Infinimmune
PrivateLast Round
Series A
Aug 11, 2026
Total Funding Raised
$87M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Infinimmune is a biotechnology company that develops human-derived antibody medicines by discovering antigen-specific antibodies from human B cells via proprietary sequencing and AI-guided engineering platforms.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Infinimmune Comparables
Compare Infinimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aureka Biotechnologies | 84% | |
| BigHat Biosciences | 83% | |
| Antiverse | 82% |
Infinimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 11, 2026 | ||||
| Seed | Dec 6, 2022 |
Key People
Founding team and executive leadership
Infinimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| Playground Global | Seed |
| Wild Tree Ventures | Series A |
| Pear VC | Seed, Series A |
| Forge Life Science Partners | Series A |
| Everbright Biofund | Series A |
| Goldcrest Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 24, 2026
Grew 38% QoQ, from 16 to 22 employees.
- Aug 11, 2026
$75M round led by Playground Global and Regeneron Ventures.
Recent news
Latest coverage and updates
- is_developingAug 16, 2026
Infinimmune is developing human-derived antibody medicines.
- receives_financingAug 11, 2026
Infinimmune received financing of $75M in Series A on Aug 11th '26.
Infinimmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Infinimmune's valuation, stock price, and market status.
Is Infinimmune a public or private company?
Infinimmune is a private company.
What is the current stock price of Infinimmune?
Infinimmune is a private company with no public stock price. No recent secondary market data is available.
How much is Infinimmune worth (valuation)?
Valuation information for Infinimmune is not publicly available.
Can I buy Infinimmune stock?
Infinimmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Infinimmune's last funding round?
Infinimmune's most recent funding round was Seed on December 6, 2022.
Who are the main investors in Infinimmune?
Key investors in Infinimmune include Playground Global.
Will Infinimmune IPO soon?
No public IPO plans have been announced for Infinimmune.
How can I track Infinimmune secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Infinimmune's secondary market activity and sign up for updates.